Epitalamin

Epithalamin

Grade D: Preclinical or anecdotal only

TL;DR: Epitalamin is a polypeptide extract from bovine pineal tissue, studied primarily by a single research group in Russia (Khavinson and colleagues) over several decades. The entire human evidence base originates from that group; no independent Western replication exists. The most-cited human study followed elderly subjects over several years and reported reduced mortality in treatment arms, but it was not a blinded RCT by modern standards, and the methodology has not been peer-reviewed outside the originating institution. Preclinical data in rodents and fruit flies show lifespan extension and effects on melatonin and free-radical markers, but animal findings of this kind have a poor track record of translating to humans. In the absence of independent replication, the human evidence must be treated as preliminary at best.

Key Takeaways

Grade D: Preclinical or anecdotal only
Not FDA approved: No FDA approval or IND status identified; not listed on any approved drug or biologics database.
Compounding: Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Mechanism

Proposed to act as a peptide bioregulator that modulates pineal gland function, influencing melatonin biosynthesis and antioxidant activity, though the receptor-level mechanism in humans has not been established.

Evidence

Epitalamin is a polypeptide extract from bovine pineal tissue, studied primarily by a single research group in Russia (Khavinson and colleagues) over several decades. The entire human evidence base originates from that group; no independent Western replication exists. The most-cited human study followed elderly subjects over several years and reported reduced mortality in treatment arms, but it was not a blinded RCT by modern standards, and the methodology has not been peer-reviewed outside the originating institution. Preclinical data in rodents and fruit flies show lifespan extension and effects on melatonin and free-radical markers, but animal findings of this kind have a poor track record of translating to humans. In the absence of independent replication, the human evidence must be treated as preliminary at best.

Safety and risks

No serious adverse events were reported in the published Russian studies, but the safety monitoring methodology in those trials is not described in detail available to outside reviewers. Effects on gonadotropic and serotonin pathways were observed in animal studies; clinical significance in humans is unknown. The product is a crude peptide extract, not a defined single molecule; batch-to-batch consistency and contamination risk in unregulated supply chains are real concerns. Long-term immunological effects of repeated exposure to a bovine-derived peptide mixture have not been characterized. No pharmacokinetic data in humans is available in the peer-reviewed literature. Not studied in pregnant or breastfeeding individuals, or in those with active malignancy, autoimmune conditions, or on immunosuppressive therapy.

Interactions

No human interaction data available. Theoretical concern with melatonin-affecting drugs (benzodiazepines, beta-blockers, SSRIs) given proposed mechanism; not verified.

Compounding legality

Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Sources

Epitalamin is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).